MEI Pharma

MEIP NASDAQ
3.050
+0.010
+0.33%
Closed 16:00 05/23 EDT
Open
3.000
Prev Close
3.040
High
3.080
Low
2.920
Volume
176.05K
Avg Vol (3M)
176.92K
52 Week High
5.14
52 Week Low
1.820
% Turnover
0.25%
Market Cap
217.44M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers MEI Pharma MEIP stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
MORE >

Recently

Name
Price
%Change